CureVac SE
🏢 View company profile →55Patents
53Active
55Granted
64Portfolio score
Filing activity: May 13, 2016 → Aug 12, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11576966B2 | Coronavirus vaccine | Chemistry; Metallurgy | 13 | Active |
| US11596686B2 | Coronavirus vaccine | Chemistry; Metallurgy | 13 | Active |
| US11596699B2 | RNA encoding an antibody | Emerging Cross-Sectional Technologies | 8 | Active |
| US11602557B2 | Bunyavirales vaccine | Emerging Cross-Sectional Technologies | 8 | Active |
| US11542490B2 | RNAs for wound healing | Chemistry; Metallurgy | 7 | Active |
| US11525158B2 | Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA | Chemistry; Metallurgy | 7 | Active |
| US11524066B2 | Henipavirus vaccine | Chemistry; Metallurgy | 7 | Active |
| US11559570B2 | Prime-boost regimens involving administration of at least one mRNA construct | Emerging Cross-Sectional Technologies | 7 | Active |
| US11739125B2 | Respiratory syncytial virus (RSV) vaccine | Chemistry; Metallurgy | 6 | Active |
| US11608513B2 | Method for adding cap structures to RNA using immobilized enzymes | Chemistry; Metallurgy | 6 | Active |
| US11965000B2 | Respiratory syncytial virus (RSV) vaccine | Chemistry; Metallurgy | 5 | Active |
| US11692002B2 | RNA sequence adaptation | Emerging Cross-Sectional Technologies | 5 | Active |
| US11739335B2 | Nucleic acids encoding CRISPR-associated proteins and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US11690910B2 | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen | Emerging Cross-Sectional Technologies | 4 | Active |
| US11697816B2 | Artificial nucleic acid molecules | Chemistry; Metallurgy | 4 | Active |
| US11872280B2 | RNA vaccine against SARS-CoV-2 variants | Chemistry; Metallurgy | 4 | Active |
| US11918643B2 | RNA vaccine against SARS-CoV-2 variants | Chemistry; Metallurgy | 4 | Active |
| US11723967B2 | Zika virus vaccine | Emerging Cross-Sectional Technologies | 3 | Active |
| US11761009B2 | Artificial nucleic acid molecules for improved protein expression | Emerging Cross-Sectional Technologies | 3 | Active |
| US11786590B2 | Rotavirus vaccines | Chemistry; Metallurgy | 3 | Active |
| US12097253B2 | RSV RNA molecules and compositions for vaccination | Chemistry; Metallurgy | 1 | Active |
| US12138348B2 | Dry powder composition comprising long-chain RNA | Human Necessities | 1 | Active |
| US12318486B2 | Dry powder composition comprising long-chain RNA | Human Necessities | 1 | Active |
| US12178863B2 | Combination of vaccination and OX40 agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US12194089B2 | Coronavirus vaccine | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.